View Older Stories View More Recent Stories
-
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief
-
Aspire Biopharma implements 1-for-40 reverse stock split
-
Aspire Biopharma Announces Reverse Stock Split
-
Aspire Biopharma director Ajjarapu resigns from board
-
Aspire Biopharma receives FDA guidance for sublingual aspirin drug
-
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)
-
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine
-
Aspire Biopharma gets Nasdaq extension to meet listing requirements
-
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
-
Aspire Biopharma submits FDA request for sublingual aspirin drug
-
Aspire Biopharma Provides Q3 2025 Business Update
-
Aspire Biopharma (ASBP) files for 41.5M share offering by selling stockholders
-
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
-
Aspire BioPharma adds Dr. Mark Jaroszeski to scientific team
-
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member
-
Aspire Biopharma discusses partnerships at CPHI Frankfurt trade show
-
Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin
-
Aspire Biopharma files omnibus patent application for sublingual drug delivery
-
Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform
-
Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025
-
Aspire Biopharma sets timeline for FDA submission of sublingual aspirin
-
Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED
-
Aspire Biopharma (ASBP) files for up to 147.18M share offering by selling stockholders
-
Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product
-
Aspire Biopharma orders 2 million servings of BUZZ BOMB supplement
-
Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement
-
Aspire Biopharma reports faster-acting sublingual aspirin in heart attack trial
-
Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
-
Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
-
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20
-
Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World
-
Aspire Biopharma launches e-commerce site for BUZZ BOMB supplement
-
Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement
-
Aspire Biopharma to debut BUZZ BOMB supplement at fitness conventions
-
Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World
-
Aspire Biopharma receives positive feedback on sublingual pre-workout supplement
-
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement
-
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
-
Aspire Biopharma (ASBP) Appoints Michael Howe as New CEO, Kraig Higginson Steps Down
-
Aspire Biopharma (ASBP) appoints Michael Howe as CEO
-
Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer
-
Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025
-
Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
-
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21
-
Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
-
Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17
-
Aspire Biopharma (ASBP) Commences Initial Production of its Pre-Workout Performance Supplement
-
Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement
-
Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
-
Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal
